c-FLIP expression in bladder urothelial carcinomas: Its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations

Urology

Volumn 63, Issue 6, 2004, Pages 1198-1204

  Korkolopoulou, Penelope ^b   Goudopoulou, Athina ^b   Voutsinas, Gerassimos ^b   Thomas Tsagli, Euphemia ^b   Kapralos, Panagiotis ^b   Patsouris, Efstratios ^b   Saetta, Angelica A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLICE INHIBITORY PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; EXON; FEMALE; GENE SEQUENCE; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CARCINOMA; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 2942605086     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.01.007     Document Type: Article

References (31)

1. Jackel M.C. Genetic control of programmed cell death (apoptosis) prospects for biological tumor staging? HNO. 46:1998;614-625
2. Itoh N., Yonehara S., Ishii A., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233-243
3. Suda T., Takahashi T., Golstein P., et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1177
4. Strand S., Hofmann W.J., Hug H., et al. Lymphocytic apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells a mechanism of immune evasion? Nat Med. 2:1996;1361-1366
5. Nicholson D.W., Thornberry N.A. Caspases killer proteases. Trends Biochem Sci. 8:1997;299-306
6. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumors. 5th ed:1997;Wiley, New York
7. Korkolopoulou P., Lazaris A.C., Konstantinidou A.-E., et al. Differential expression of bcl-2 family proteins in bladder carcinomas relationship with apoptotic rate and survival. Eur Urol. 41:2002;274-283
8. Lee S.H., Shin M.S., Park W.S., et al. Alteration of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:1999;3068-3072
9. Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 30:342-345, 2002
10. Chopin D., Barei-Moniri R., Maille P., et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol. 162:2003;1139-1149
11. Bullani R.R., Huard B., Viard-Leveugle I., et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol. 117:2001;360-364
12. Perabo F.G.E., Kamp S., Schmidt D., et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer. 84:2001;1330-1338
13. Lee S.H., Lee J.Y., Park W.S., et al. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int. 83:1999;698-702
14. Ito Y., Monden M., Takeda T., et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer. 82:2000;1211-1217
15. Frankel B., Longo S.L., Ryken T.C. Human astrocytomas co-expressing Fas and Fas ligand also produce TGFb2 and Bcl-2. J Neurooncol. 44:1999;205-212
16. Pitti R.M., Marsters S.A., Lawrence D.A., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703
17. Sato T., Irie S., Kitada S., et al. FAP-1 a protein tyrosine phosphatase that associates with Fas. Science. 268:1995;411-415
18. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195
19. Tamm I., Kornblau S.M., Segall H., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 6:2000;1796-1803
20. Ashkenazi A., Dixit V.M. Death receptors signaling and modulation. Science. 281:1998;1305-1308
21. Abdel-Rahman W., Arends M., Morris R., et al. Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas. Cell Death Differ. 6:1999;387-388
22. Bertoni F., Conconi A., Luminari S., et al. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. Leukemia. 14:2000;446-448
23. Puiu L., Petrakou E., Apostolidou A., et al. Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer. Cancer Lett. 194:2003;91-97
24. Scaffidi C., Schmitz I., Krammer P.H., et al. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 274:1999;1541-1548
25. Ryu B.K., Lee M.G., Chi S.G., et al. Increased expression of c-FLIP (L) in colonic adenocarcinomas. J Pathol. 194:2001;15-19
26. Djerbi M., Screpanti V., Catrina A.I., et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 190:1999;1025-1032
27. Kataoka T., Budd R.C., Holler N., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol. 10:2000;640-648
28. Lee S.H., Kim S.H., Kim S.Y., et al. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS. 111:2003;309-314
29. Thomas R.K., Kallenborn A., Wickenhauser C., et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol. 160:2002;1521-1528
30. Jonsson G., Paulie S., Grandien A. High level of c-FLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res. 23:2003;1213-1218
31. Pryor J.P. Factors influencing the survival of patients with transitional cell tumors of the urinary bladder. Br J Urol. 45:1973;586-591